KR20150107695A - Compositions comprising adipose-derived mesenchymal stem cell overexpressing gcp-2 gene for treating ischemic disease - Google Patents

Abstract

The present invention relates to adipose-derived mesenchymal stem cells (ASCs) overexpressing a granulocyte chemotactic protein-2 (GCP-2) gene. The adipose-derived mesenchymal stem cells according to the present invention overexpress a VEGF-A and an HGF gene to promote angiogenesis, reduce a left ventricular end diastolic diameter (LVEDD) and a left ventricular end systolic diameter (LVESD) value, increase a left ventricular ejection fraction (LVEF) value to improve a cardiac function, and increase vascular density of an ischemic area, thereby being valuably usable in treating an ischemic disease.

Description

TECHNICAL FIELD The present invention relates to a composition for treating ischemic diseases comprising lipid mesenchymal stem cells overexpressing a GCP-2 gene. More particularly, the present invention relates to a composition for treating ischemic diseases comprising lipid mesenchymal stem cells overexpressing GCP-

The present invention relates to a composition for treating ischemic diseases comprising lipid mesenchymal stem cells, and more particularly to a composition for treating ischemic diseases comprising lipid mesenchymal stem cells overexpressing the GCP-2 gene.

Despite many recent studies in cardiovascular medicine, ischaemic cardiovascular disease is one of the most serious health problems in Westernized societies (Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics. 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486).

Recent advances in stem cell biology have made cell-based therapies an attractive new strategy for the treatment of injured organs and tissues (Kamihata H, Matsubara H, Nishiue T, et al., Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001; 104: 1046-52).

In particular, since mesenchymal stem cells (MSCs) are an important source of adult stem cells, MSCs have been proposed for potential treatment of cardiovascular diseases (Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ et al. Multilineage cells from human adipose tissue: implications for cell-based therapies Tissue Eng 2001; 7: 211-228. Rejman J, Traktuev D, Li J, Merfeld-Clauss S, and Temm-Grove CJ, Bovenkerk, in Cell Physiol Biochem 2004; 14: 311-324. Human adipose tissue-to-cell adhesion molecule (MEC) has been shown to induce apoptosis in human adipose tissue [1], [2], [ derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol Biochem 2006; 17: 279-290. / Byun KH , Kim SW, Is stem cell-based therapy on or out for cardiac disease, Korean Circ J 2009; 39: 87-92.).

Adipose tissue-derived MSCs (ASCs) from fat cells have been widely studied because of their ease of isolation from patients. However, recent studies related to ASCs have reported problems that are difficult to apply to clinical treatments, such as the low survival rate of transplanted cells that have been demonstrated in the ischaemic heart (Shake JG, Gruber PJ, et al : A study of mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects Ann Thorac Surg 2002; 73: 1919-1925. Cho HJ, et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart J Exp Med 2007; 204: 3257-3269. / Kang HJ, et al. Magnetic bionanoparticle enhances homing of endothelial progenitor cells in mouse hindlimb ischemia. Korean Circ J 2012; 42: 390-396).

On the other hand, chemotactic cytokines (chemokines) play an important role in immune responses, homeostasis, tumorigenesis, neovascularization, etc. (Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250: 104. / Rote, von Andrian U. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928). It has been reported that GCP-2 (granulocyte chemotactic protein-2, GCP-2 / CXCL6) is expressed in vascular endothelial cells and fibroblasts and mesenchymal cells showing angiogenic properties (Wuyts A, et al., Lab Invest 2003; 83: 23-34).

In the present invention, a strategy of over-expression of GCP-2 in stem cells could be a new method for enhancing angiogenesis and cell viability, and efforts were made to find a therapeutic agent for a new ischemic disease. As a result, adipose-derived mesenchymal stem cells (ASCs) overexpressing the GCP-2 gene promoted angiogenesis by overexpressing the VEGF-A and HGF genes, and the IGF-1 and Akt-1 genes (LVEDD) and left ventricular end-systolic diameter (LVESD). In addition, the vascular endothelial growth factor (VEGF) and the vascular endothelial growth factor (vWF) Decrease in heart rate, increase in left ventricular ejection fraction (LVEF) value to improve cardiac function, increase vascular density in ischemic area, and confirm therapeutic efficacy against ischemic diseases Thereby completing the present invention.

Accordingly, it is an object of the present invention to provide a method for the treatment and prophylaxis of gastrointestinal stem cells capable of overexpressing the GCP-2 gene to express and secrete genes and proteins involved in cell migration and angiogenesis, reduce myocardial infarction, I have to.

It is another object of the present invention to provide a pharmaceutical composition for the treatment of ischemic diseases comprising lipid mesenchymal stem cells overexpressing the GCP-2 gene.

It is still another object of the present invention to provide a method for treating ischemic diseases using lipid mesenchymal stem cells overexpressing the GCP-2 gene.

Another object of the present invention is to provide a use of lipojunctional stem cells overexpressing the GCP-2 gene for the preparation of medicament for the treatment of ischemic diseases.

According to one aspect of the present invention, there is provided a pharmaceutical composition comprising adipose-derived mesenchymal stem cells (ASCs) overexpressing a granulocyte chemotactic protein-2 (GCP-2) gene or its conditioned medium Effective amount; And a pharmaceutically acceptable carrier. The present invention also provides a pharmaceutical composition for the treatment of ischemic diseases.

In the present invention, the GCP-2 gene includes all the GCP-2 genes derived from an animal. As long as the GCP-2 protein binds to the GCP-2 receptor so as to function as a chemokine, , Insertions, non-conservative or conservative substitutions, or combinations of these.

The vector used for introducing the GCP-2 gene of the present invention into a stem cell includes a plasmid vector, a cosmid vector, a viral vector and the like. Suitable expression vectors include signal sequences or leader sequences for membrane targeting or secretion in addition to expression control elements such as promoter, operator, initiation codon, termination codon, polyadenylation signal, enhancer, and can be prepared variously according to the purpose.

The GCP-2 gene may be directly injected into known methods in the art, for example, naked DNA in vector form (Wolff et al., Science, 247: 1465-8, 1990: Wolff et al., J Cell Sci. 103: 1249-59, 1992), liposomes, cationic polymers, and the like.

The present inventors transplanted the GCP-2 gene into a viral vector and transfected the adipocyte mesenchymal stem cells and overexpressed the GCP-2 gene through myocardial infarction model using NOD / SCID mouse The ability of stem cells to treat mesenchymal stem cells was studied. In addition, grafted mesenchymal stem cell cells overexpressing the GCP-2 gene in the ischemic area were found to be involved in changes in gene expression, secretion of multiple paracrine factors, cell migration and angiogenesis And the reduction of myocardial infarction. In addition, the injection of grafted mesenchymal stem cells (GCP-2) overexpressing the GCP-2 gene promoted the treatment of ischemic diseases.

In addition, according to a preferred embodiment of the present invention, the adipose-derived mesenchymal stem cells (ASCs) used in the composition of the present invention are more effective than the normal ASCs cells in which GCP-2 is not transformed, It is characterized by promoting angiogenesis by overexpressing the pro-angiogenic factors VEGF-A and HGF genes.

In addition, according to a preferred embodiment of the present invention, the lipid mesenchymal stem cells used in the composition of the present invention have anti-apoptotic / cell survival factors, as compared with normal ASCs cells in which GCP-2 is not transformed ) ≪ / RTI > IGF-1 and Akt-1 gene to inhibit apoptosis.

In addition, according to a preferred embodiment of the present invention, the lipid mesenchymal stem cells used in the composition of the present invention overexpress eNOS (endothelial nitric oxide synthase), Tie-2, and vWF (von Willebrand factor) (endothelial cell).

According to a preferred embodiment of the present invention, the lipid mesenchymal stem cells used in the composition of the present invention reduce the left ventricular end diastolic diameter (LVEDD) and the left ventricular end systolic diameter (LVESD) fraction can be increased to promote improvement of cardiac function.

Also, according to a preferred embodiment of the present invention, the fat mesenchymal stem cells used in the composition of the present invention are characterized by increasing the vascular density of the ischemic area.

In addition, according to a preferred embodiment of the present invention, the conditional medium of the fat mesenchymal stem cells used in the composition of the present invention promotes the proliferation of fibroblasts and promotes wound closure of fibroblasts And the blood circulation rate is increased.

The ischemic diseases of the present invention include ischemic heart disease, ischemic myocardial infarction, ischemic heart failure, ischemic enteritis, ischemic vascular disease, ischemic eye disease, ischemic retinopathy, ischemic glaucoma, ischemic renal failure, ischemic stroke, Includes ischemic heart disease, ischemic myocardial infarction, or ischemic heart failure.

According to another aspect of the present invention, there is provided a pharmaceutical composition comprising adipose-derived mesenchymal stem cells (ASCs) overexpressing a granulocyte chemotactic protein-2 (GCP-2) gene or its conditioned medium Effective amount; And a pharmaceutically acceptable carrier, to an animal other than a human, comprising the step of administering to a mammal an ischemic disease.

The composition of the present invention may comprise 1.0 x 10 ⁴ to 1.0 x 10 ⁸ , preferably 1.0 x 10 ⁵ to 1.0 x 10 ⁷ , more preferably 1.0 x 10 ⁶ cells per ml.

In addition, the composition of the present invention can be formulated into a unit dosage form suitable for administration to a patient in the body according to a conventional method, and the composition can be administered by one or several administrations, ≪ / RTI > Examples of suitable formulations include injections such as injection ampoules, injection bags, etc., injected as parenteral administration preparations, and the like. The injectable ampoule may be mixed with the injection solution immediately before use. As the injection solution, physiological saline, glucose, mannitol, and Ringer's solution may be used. The injection bag may be made of polyvinyl chloride or polyethylene.

In addition to the active ingredient, the pharmaceutical preparation may further contain one or more pharmaceutically acceptable carriers. For example, in the case of an injection, a preservative, an anhydrous agent, a solubilizer or a stabilizer may be added. In the case of a preparation for topical administration Bases, excipients, lubricants or preservatives, and the like.

The composition or pharmaceutical preparation of the present invention may be administered by a conventional method of administration, preferably by a parenteral administration method, and may be administered, for example, by injection, Or can be implanted directly into the subcutaneous tissue.

The daily dose of the cells of the present invention may be administered once or several times in a dose of 1.0 x 10 ⁵ to 1.0 x 10 ⁷ , preferably 1.0 x 10 ⁵ to 1.0 x 10 ⁶ cells / kg. However, the actual dosage may vary depending on the disease, the severity of the disease, the route of administration, the weight of the patient, age and sex, and the like.

As described above, the composition of the present invention overexpresses VEGF-A and HGF genes to promote angiogenesis, overexpresses IGF-1 and Akt-1 genes to inhibit apoptosis, and inhibits eNOS, Tie-2, and vWF (LVEF), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD), and increased left ventricular ejection fraction (LVEF) May be useful in the treatment of ischemic diseases by improving cardiac function and increasing vascular density in the ischemic area.

FIG. 1 is a graph showing gene expression patterns associated with angiogenesis and anti-apoptosis through qRT-PCR analysis after treatment with hASCs / GCP-2 cells.
Figure 2a is an analysis of fibroblast wound closure after treatment with conditioned media.
FIG. 2B is an analysis of fibroblasts proliferating ex vivo after treatment with conditioned media. FIG.
FIG. 3A is an analysis of the angiogenic ability in vitro. FIG.
FIG. 3B is a photograph showing EC-specific gene expression changes of vascular endothelial cell-specific genes through RT-PCT.
FIG. 3c is a graph showing quantitative results of expression of EC-specific gene expression changes in vascular endothelial cells.
4 is a graph showing the results of echocardiography.
FIG. 5A is a comparative analysis of the infarct scar area after hASCs / GCP-2 cell transplantation. FIG.
FIG. 5B is a comparative analysis of blood vessel density near the border where infarction occurred after hASCs / GCP-2 cell transplantation.
FIG. 5c shows cell survival analysis by TUNEL analysis after hASCs / GCP-2 cell transplantation. FIG.
FIG. 5D is a graph showing the analysis of VEGF-A expression through qRT-PCR analysis. FIG.

Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and thus the scope of the present invention is not construed as being limited by these embodiments.

Example 1. Preparation of Experimental Methods and Experimental Materials

1-1. Cell culture

Isolation of human adipose derived mesenchymal stem cells (hASCs) was carried out using CHO HH. (Cho HH, Kim YJ, et al.) The role of chemokines in proangiogenic action induced by human adipose tissue-derived mesenchymal stem cells in the murine model of hindlimb ischemia Cell Physiol Biochem 2009; 24: 511 -518). All protocols, including human samples, were approved by the Institutional Review Boards of DongAh and Pusan National University. Cells were cultured in medium [a-MEM, 10% fetal bovine serum (FBS), 100 U / mL of penicillin, and 100 mg / mL of streptomycin] and maintained at 37 ° C and 5% CO ₂ . All experiments were performed with 3- to 5-pass subcultured hASCs. Human umbilical vein endothelial cells (HUVECs) and normal human dermal fibroblasts (HDFs) were purchased from ATCC (Manassas, VA, USA).

1-2. Construction and transduction of viral vectors

The hASC / GCP-2 cell line was used for the transfection. Construction of the viral vector and transduction into the cell were carried out according to the conventional method (Cho HH, et al. Cell Physiol Biochem 2009; 24: 511-518). The GCP2 gene was obtained from pCMVSPORT6-GCP2 (21C Frontier human gene bank) plasmid and cloned into the target vector pLenti6 / GCP2 using a BP / LR clonase (Invitrogen, Carlsbad, CA, USA) V5. To confirm the production of viral vectors, the entire plasmid was sequenced. 293T cells, lipofectamine Plus, Invitrogen, and packaging mix (Invitrogen) were used to introduce replication-defective lentivirus into cells. Virus samples were obtained 48 hours or 72 hours after transduction and filtered using a Millex-HV 0.45 mm PVDF filter (Millipore, Billerica, MA, USA). The virus-containing liquid phase was reacted with hASCs for 6 hours using polybrene (5 mg / mL) to induce viral cell transduction and blasticidin (10 mg / mL, Invitrogen) Were used to screen for virus-introduced cells.

1-3. RT-PCR and qRT-PCR analysis

qRT-PCR analysis was performed according to the conventional method (Kang HJ, et al. Korean Circ J 2012; 42: 390-396 / Kim SW, et al J Am Coll Cardiol 2010; 56: 593-607). Total RNA was isolated from subcultured cells three to five times. RNA-stat reagents (Iso-Tex Diagnostics, Friendswood, TX, USA) and RNA extraction kit (iNtRON Biotechnology, Korea) were used. The isolated RNA was reverse-transcribed using Taqman Reagent Reagents (Applied Biosystems, Foster City, CA, USA). The synthesized cDNA was applied to qRTPCR or RTPCR using human / mouse-specific primers and antibodies. RNA levels were quantified using a detection system (ABI PRISM 7000 Sequence Detection System, Applied Biosystems, Foster City, CA, USA). Relative mRNA expression levels were calculated based on GAPDH expression level and followed the conventional method (Kang HJ, Kim JY, et al. Korean Circ J 2012; 42: 390-396). Primer and probe sets were purchased from Applied Biosystems.

1-4. Apoptosis assay

Cell death was induced by serum deprivation (SD) for 6 hours according to the conventional method (Kim MH, Zhang HZ, Kim SW, J Mol Cell Cardiol 2011; 51: 702-712). Apoptotic cells were examined using the Annexin V-FITC binding assay kit (Oncogene, San Diego, CA, USA)

Apoptotic cells were measured using an Annexin V-FITC binding assay kit (Oncogene, San Diego, Calif., USA) and analyzed using FACScan (Becton Dickinson, San Jose, CA, USA) Respectively.

1-5. Cell migration assay

In order to carry out the cell migration assay, the conditioned medium was obtained according to conventional methods (Zhang C, et al. Clin Cancer Res 2009; 15: 4017-4027). Cells (1 × 10 ⁶ ) were inoculated into T-75 flasks and incubated with normal medium or penicillin (100 U / mL), streptomycin (100 mg / mL, Gibco), and 10% fetal bovine serum (Dulbecco's modified Eagle medium, Gibco, Grand Island, NY, USA) for 48 h until cells were filled to about 80%. The culture medium from each sample was centrifuged at 1000 g and used as a conditioned medium for experiments. HDFs were inoculated to a 24-well culture plate coated with type I collagen (0.2 mg / mL) at a density of 1 x 10 < ⁵ > / well. And, 37 ℃ enough to fill all the wells, and incubated in 5% CO ₂ for 24 hours. The cell layer was scratched using a sterile pipette tip and cultured in a conditioned medium. To measure cell mobility, five sites were randomly selected after 72 hours of scratching and photographed. The wound area was determined using a wound margin and calculated using the NIH Imaging Program (http://rsb.info.nih.gov/nih-image/).

1-6. Acute myocardial infarction induction and cell transplantation

The experiment was conducted in accordance with the Guide for the Protection and Use of Laboratory Animals (NIH Publication No. 85-23, 1996) issued by the National Institutes of Health, and the Declaration of Helsinki on human tissue and sample use. In accordance with the principles of. A mouse model of myocardial infarction (MI) was prepared according to the conventional method (Kang HJ, et al., Circ J 2012; 42: 390-396. 2010; 139: 166-172). The entire process was done with the approval of DIACUC. Regarding pain and distress, I conducted regular analgesia with advice from Dong - A University Medical Research Support Center.

12-13 week old NOD / SCID mice (NOD.CB17-Prkdc ^skid / J strain, The Jackson Laboratory, Bar Harbor, Maine, USA) were randomly divided into five groups (hASCs group treated with hASCs / GCP-2 (N = 15), PBS group (n = 15), sham-operation (n = 15) treated with anti-GCP-2-neutralizing antibodies Group (surgery without LAD ligation)].

All mice were anesthetized with 75 mg / kg ketamine, 1 mg / kg medetomidine, 600 mg / kg atropine and administered with 0.05 mg / kg buprenorphine. The depth of anesthesia was determined by measuring the respiratory rate and withdrawal reflex. Oxygen was supplied using an instrument capable of supplying 0.25-0.30 ml of air (Inspira-Advanced Safety Ventilator) at 130 rpm, which was performed by inserting a tube into the airway. The mouse was placed on the right side to allow the heart to be revealed through left thoracotomy. After removal of myocardium, a stereomicroscope was used to view the left anterior descending artery (LAD). A nylon suture (9.0 nylon suture) was used to induce occlusion of the blood vessel at a distance of 0.3 mm from the atrioventricular junction. Left ventricular parenchyma was observed after ligation to confirm the occlusion of the blood vessels.

In order to distinguish transplanted cells, cells were prepared in a 100 mm culture container at 2-3 ° C. for 15 minutes at 37 ° C. and 4 ° C. using 2 to 3 × 10 ⁶ cells per container. 4 μM Dil (chloromethyl - benzamido - 1,1 '- dioctadecyl - 3,3,3'3'-tetramethylindo-carbocyanine, Molecular Probes, USA). Neutralizing antibodies to GCP-2 (R & D Systems) were treated 1 hour before cell implantation. After acute myocardial infarction (acute myocardial infarction, AMI), the PBS containing 50ul PBS or 1 × 10 ⁶ cells were injected into the cardiac muscle. The dice selected three positions at the boundary of the infarcted part. echocardiography (ECHO) was performed on surviving experimental animals to confirm cardiac function at 4 weeks after treatment with hASCs / GCP-2 or PBS, and then dissected for tissue analysis.

1-7. Cardiac function test

Cardiac function was measured using a 15-16 MHz linear array transducer (hockey stick). The parasternal long-axis view and the short-axis view of both dressed bones have taken both M-mode and 2D (two-dimensional) ultrasound images. Left ventricular end-diastolic diameter (LVEDD), left ventricle end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF) , Kim MH, et al., Int J Cardiol 2010; 139: 166-172).

1-8. Histological and immunohistochemical analysis

After echocardiography (ECHO) was completed, all experimental animals were euthanized and dissected by injecting thiopental-sodium (40 mg / kg) into the blood vessels for tissue analysis. Treatment with an aqueous solution of 4% paraformaldehyde (PFA, Sigma-Aldrich, St Louis, MO, USA) and heart was excised and treated with paraffin (Yu LH, Kim MH, et al. Int J Cardiol 2010; 139: 166-172). Thereafter, 5 mu m transverse sections were continuously obtained for the entire left atrium, and the sections were used for Masson-Trichrome staining and immunohistochemical analysis. Four sections near the mid-papillary were obtained from each extracted heart and used for measurement and staining of the scar area. Scars were stained blue by Matheson chrome staining and quantitatively calculated using the instrument (Scan Scope CS system, Aperio Technologies, Inc., Vista, CA, USA). The unit of the area is the square of the millimeter.

The number of microvessels was measured to determine the vascular density at the infarcted border. Measurements were taken using a 400x optical microscope and performed in five sections per heart. Section was stained first with ILB4 (biotinylated ILB4, 1: 250; Vector Laboratory, Inc.) and treated with SA (streptavidin) Alexa Fluor 488 (1: 400; Invitrogen) . Five high-power fields were randomly selected in each section and the number of microvessels was measured at each section. Measurement of apoptosis in the heart was measured using a TUNEL Assay Kit (Promega). HHF35 (1: 400; Dako) was used for primary staining of muscle actin, and Cy3 (1: 500; Jackson Immunoresearch Laboratories) was used for secondary staining. The tissue sections were fixed and observed using a microscope (laser scanning confocal microscope, LSM510, Carl Zeiss). FISH (fluorescence in situ hybridization) was performed with a human X chromosome probe, Cy3-fusion (Cambio, Cambridge, UK) to observe human cells.

1-10. Statistical Analysis

All data were summarized as mean ± standard error or standard error. Student's t-test was used for comparison between the two groups. In order to analyze various factors, ANOVA with Bonferroni's multiple comparison test was used. Statistical significance was applied to values of p <0.05. All statistical analyzes were performed using SPSS v 12.0 software (SPSS, Inc., Chicago, IL, USA).

Example 2. Cell Characterization

In the analysis using subcultured cells of the fourth to sixth generations, hASCs showed spindle fibroblast morphology at the time of culture. Through FACS analysis, hASCs showed characteristic features on mesenchymal stem cells, positive for CD13, CD29, CD44, CD73, CD105 and negative for CD34 and CD45.

Example 2. Analysis of GCP-2 protein expression in hASCs / GCP-2 cells

ELISA analysis was performed to confirm GCP-2 protein secretion in hASCs / GCP-2 cells. The expression level of GCP-2 protein was significantly higher in hASCs / GCP2 cells when compared to hASCs (hASCs / GCP-2) cells treated with GCP-2 viral vectors and hASCs (1343 ± 15 vs. 125 ± 12.4 pg / mL; P <0.001, n = 7).

Example 3. Analysis of angiogenesis and anti-apoptotic properties of hASCs / GCP-2 cells

qRT-PCR was performed to analyze the angiogenic and anti-apoptotic characteristics of hASCs / GCP-2 cells. As a result, pro-angiogenic factors such as VEGF-A and HGF (hepatocyte growth factor) were highly expressed in hASCs / GCP-2 cells compared with hASCs cells (29.9 and 2.1 times, respectively) 1A). In addition, chemokines such as IL-8 and GCP-2, which play an important role in neovascularization, were also up-regulated (12.5 and 9.0 fold, respectively). In addition, anti-apoptotic / cell survival factors such as IGF-1 and Akt-1 were highly expressed (254.0 and 3.1 times, respectively) in comparison with the control group.

To examine the cytoprotective effect of hASCs / GCP-2 cells, an in vitro apoptosis assay was performed. As a result, the number of apoptotic cells in the hASCs / GCP-2 cell group was greatly reduced compared to the hASCs and HUVECs cell lines (Fig. 1B).

Based on these results, it was confirmed that hASCs / GCP-2 cells express high levels of genes related to angiogenic and anti-apoptotic genes.

Example 4. Analysis of cell migration, proliferation, and improvement of blood flow in hASCs / GCP-2 culture medium

An in vitro scratch assay was performed to determine whether secreted proteins from hASCs / GCP-2 cells could promote cell migration during neovasculogenesis. Experiments were performed in comparison with HUVECs, and hASCs, and measured 72 h later. The hMSCs / GCP-2 conditioned medium significantly increased the rate of wound closure of human dermal fibroblasts (20.2 ± 2.1 vs. 37.9 ± 4.9, 50.9 ± 4.6, n = 4) (Figure 2A). In addition, the proliferation rate of fibroblast cultured in hASCs / GCP-2 medium was greatly increased (FIG. 2B).

Next, in order to clarify whether it is associated with the in vivo paracrine mechanism, the effect of the secreted protein was examined using an ischaemic hindlimb mouse model. LDPI analysis showed that blood circulation rate increased significantly in the legs injected with hASCs / GCP-2 conditioned medium after 21 days.

Example 5 in virto of hASCs / GCP-2 cells. Analysis of endothelial cell differentiation potential

To investigate the EC differentiation potential of hASCs / GCP-2 cells and control hASCs cells, each cell type was cultured in EGM-2 medium.

On the 10th day of hASCs / GCP-2 and hASCs cells differentiation into vascular endothelial cells, we found a very interesting phenomenon. Both hASCs / GCP-2 and hASC cells formed linear tubular structures, consistent with the fact that these cells contribute to vasculogenesis.

In particular, hASCs / GCP-2 cells were observed to differentiate into fully mature blood vessels by forming a unique egg-shaped structure (FIG. 3A).

UEA-1 lectin and KDR (kinase insert domain receptor), which are used as EC-specific markers for vascular endothelial cells, were stained to identify these tubular cells.

As a result of immunocytochemistry analysis, a greater number of vascular endothelial cell markers were identified in the hASCs / GCP-2 cell treated group. These results indicate that hASCs / GCP-2 cells are more potent than vascular endothelial cells And the ability to differentiate was confirmed.

Next, RT-PCR was performed to measure vascular endothelial cell-specific gene expression (EC-specific gene expression) upon differentiation of vascular endothelial cells. HASCs / GCP-2 and hASCs in the undifferentiated state expressed eNOS (endothelial nitric oxide synthase) and Tie-2. Tie-2 was expressed at high levels in hASCs / GCP-2, particularly in the non-differentiated state (FIGS. 3B and 3C). After 10 days of hASCs / GCP-2 initiation into vascular endothelial cells, vWF (Von Willebrand factor) expression gradually increased.

When the degree of gene expression was quantified, eNOS, Tie-2, and vWF expression levels were highly measured in hASCs / GCP-2 over 5 to 15 days (Fig. 3C). These results indicate that hASCs / GCP-2 has great potential for differentiation into vascular endothelial cells.

Example 6. Analysis of therapeutic effect of hASCs / GCP-2 cells in the MI model

To investigate the therapeutic potential of hASCs / GCP-2 cells for ischaemic heart, we induced myocardial infarction (MI) through coronary ligation in NOD / SCID mice. And 1 × 10 ⁶ cells were injected into the peri-infarct zone of the ventricular wall. For comparison, PBS was injected into the control group (n = 15, each group). Echocardiography (ECHO) was performed at 4 weeks after transplantation.

RESULTS: LVEDD (3.96 ± 0.47 vs. 3.94 ± 0.46 mm; P = 0.009) and LVESD (LVESD) were significantly higher in the hASCs / 2.02 +/- 0.47 vs. 2.96 +/- 0.41 mm; P < 0.001).

LVEF was also higher in the hASCs / GCP-2 injected group than in the hASCs, PBS, and GCP-2 neutralizing antibody treated hASCs / GCP-2 cells (72.2 ± 7.5 vs P = 0.022, vs. 48.1 + 5.0%, P <0.001, vs. 63.1 + 8.3%, P = 0.018). In the group injected with hASCs / GCP-2, the degree of decrease in the wound area was also measured in comparison with hASCs or PBS-injected group (FIG. 5A).

In addition, vascular density at the infarcted interface was higher than that of hASCs / PBS-injected group when hASCs / GCP-2 cells were injected (FIG. 5B).

To analyze the mechanism of treatment for heart recovery when hASCs / GCP-2 cells were injected, we measured the degree of cell necrosis at sites of hypoxia-infarct infarction. Apoptotic cells were detected by TUNEL (terminal deoxynucleotidyl transferase mediated dUTPbiotin nick end labeling) assay and the control and hASCs / GCP-2 infusion groups were measured over 3 days.

The muscle actin was stained with triple staining to confirm that the apoptotic cells were myocytes and there was a large difference in the hearts injected with hASCs / GCP-2 cells compared to the control group (Fig. 5C).

Based on these results, it was confirmed that a protective effect of hASCs / GCP-2 cells when used in transplantation of myocardial muscle damaged by myocardial infarction was confirmed.

Example 7. Analysis of angiogenic factor expression after hASCs / GCP-2 cell transplantation

In order to observe changes in cytokine expression after transplantation of hASCs / GCP-2 into the ischemic heart, myocardial infarction was induced in the mouse. Then euthanasia was performed and cardiac tissue was isolated. As a result, the expression levels of VEGF-A and Ang (angiopoietin) -1 were significantly increased in hASCs / GCP-2 cells injected group compared to hASCs cells and PBS injected group (FIG.

Example 8. Analysis of engraftment and EC trans-differentiation of hASCs / GCP-2 cells

To evaluate engraftment and survival potency when hASCs / GCP-2 was injected, myocardial infarction model (MI model) was constructed using NOD / SCID mouse. 1 x 10 &lt; ⁶ &gt; dil-labeled cells were injected at the edge of the ischemic heart. Results confirmed by immunohistochemistry. The hASCs / GCP-2 cell treated group had a high engraftment rate (152.3 ± 52.5) (Fig. 6A) when compared to the hASCs cells (84.1 ± 54.2) treated group. In order to determine the survival rate of the transplanted cells, ischemic heart was treated with enzyme and flow cytometric analysis was performed. Analysis was performed at 4 weeks after cell transplantation. The results showed that the hASCs / GCP-2 (0.47 ± 0.28) injected group had a higher graft rate than the hASCs (0.12 ± 0.19) treated group.

Next, to evaluate the ability of hASCs / GCP-2 cells to differentiate into vascular endothelial cells in vivo, the vascular endothelial cell protein ILB4 (isolectin B4) was subjected to immunostaining. Double-positive cells were observed in both Dil and ILB4 at 4 weeks after transplantation of the dil-labeled cells. A larger number of cells were observed in the ischemic heart treated with hASCs / GCP-2 cells compared to the hASCs treated group (4.8 ± 2.1 vs. 1.3 ± 1.2; P = 0.006, n = 7) 6B).

Three-dimensional z-stacked images were also used to confirm that hASCs / GCP-2 cells were present in the vascular structure and vascular endothelial marker expression was also observed. These results show that hASCs / GCP-2 cells differentiated into vascular endothelial cells (Fig. 6C).

FISH analysis using a human X chromosome was performed to confirm whether ILB4-expressing cells were actually transplanted hASCs / GCP-2 cells.

By confirming that ILB4-positive cells were from human donors by FISH, it was confirmed that hASCs / GCP-2 cells were differentiated into vascular endothelial cells. These results indicate that hASCs / GCP-2 cell line has high survival rate and ability to differentiate into endothelial cells.

Claims (9)

A pharmaceutically effective amount of adipose-derived mesenchymal stem cells (ASCs) or its conditioned media overexpressing GCP-2 (Granulocyte chemotactic protein-2) gene; &Lt; / RTI &gt; and a pharmaceutically acceptable carrier. The pharmaceutical composition for treating ischemic diseases according to claim 1, wherein the adipose-derived mesenchymal stem cells (ASCs) overexpress VEGF-A and HGF genes to promote angiogenesis. The pharmaceutical composition for the treatment of ischemic diseases according to claim 1, wherein the adipose-derived mesenchymal stem cells (ASCs) overexpress the IGF-1 and Akt-1 genes to inhibit apoptosis. 2. The method according to claim 1, wherein the adipose-derived mesenchymal stem cells (ASCs) are capable of overexpressing eNOS, Tie-2, and vWF genes and differentiating into endothelial cells &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof. The method according to claim 1, wherein the adipose-derived mesenchymal stem cells (ASCs) decrease the left ventricular end diastolic diameter (LVEDD) and the left ventricular end systolic diameter (LVESD) ) &Lt; / RTI &gt; of the compound of formula (I). The pharmaceutical composition for the treatment of ischemic diseases according to claim 1, wherein the adipose-derived mesenchymal stem cells (ASCs) increase the vascular density of the ischemic area. The method of claim 1, wherein the conditioned media promotes proliferation of fibroblasts, promotes wound closure of fibroblasts, and increases blood circulation rate. A pharmaceutical composition. The method of claim 1, wherein the ischemic disease is selected from the group consisting of ischemic heart disease, ischemic myocardial infarction, ischemic heart failure, ischemic colitis, ischemic vascular disease, ischemic eye disease, ischemic retinopathy, ischemic glaucoma, ischemic renal failure, ischemic stroke, &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof. A pharmaceutically effective amount of adipose-derived mesenchymal stem cells (ASCs) or its conditioned media overexpressing GCP-2 (Granulocyte chemotactic protein-2) gene; And a pharmaceutically acceptable carrier, to an animal other than a human.

Images